10-Q: Avenue Therapeutics Q3 2025: Delisting, Asset Sales, Losses

Avenue Therapeutics reports significant net loss reduction in Q3 2025, driven by asset sales and cost cuts, amidst Nasdaq delisting and going concern doubts.

Summary

• Net loss significantly reduced for the three months ended September 30, 2025, to $0.692 million from $3.087 million in the prior year.
• Net loss for the nine months ended September 30, 2025, improved to $2.221 million from $10.137 million in the prior year.
• Generated $1.4 million in other revenue for the nine months ended September 30, 2025, primarily from the AnnJi license termination.
• Research and development expenses decreased by 92% to $0.177 million for the three months and by 87% to $0.780 million for the nine months, largely due to the termination of the AJ201 program.
• General and administrative expenses decreased by 34% to $0.547 million for the three months and by 18% to $2.955 million for the nine months.
• Nasdaq delisted the company's common stock on March 19, 2025, due to a violation of the $2.5 million stockholders' equity rule, with trading now on OTCID.
• Terminated the AJ201 license agreement with AnnJi on April 24, 2025, receiving $1.6 million in payments and potential future milestones/royalties.
• Sold Baergic Bio, Inc. and its BAER-101 (now AXS-17) program to Axsome Therapeutics for an upfront payment of $0.3 million and potential future milestone and royalty payments, effective November 5, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, requiring additional funding for the IV tramadol Phase 3 safety study.

Sentiment

Score: 3

Explanation: While net losses decreased and some revenue was generated from asset sales, the delisting from Nasdaq, explicit going concern warning, and the need for significant external funding for its remaining core asset (IV tramadol) paint a very challenging picture for the company's future viability and growth. The asset sales, while providing some cash, also reduce the pipeline.

Positives

• Significant reduction in net loss for both the three months ($2.395 million improvement) and nine months ($7.916 million improvement) ended September 30, 2025, compared to the prior year.
• Generated $1.4 million in other revenue for the nine months ended September 30, 2025, from the AnnJi license termination, which was absent in the prior year.
• Substantial decrease in research and development expenses due to the termination of the AJ201 program and sale of BAER-101.
• Agreement with the FDA on the Phase 3 safety study protocol and statistical analysis for IV tramadol.
• Sale of Baergic Bio, Inc. and BAER-101 to Axsome Therapeutics provides an upfront payment of $0.3 million and potential future milestone and royalty streams.

Negatives

• Nasdaq delisted the company's common stock on March 19, 2025, due to failure to maintain minimum stockholders' equity, negatively impacting liquidity and market price.
• Substantial doubt about the company's ability to continue as a going concern due to an accumulated deficit of $104.8 million and ongoing operating losses.
• Reliance on securing additional funding for the IV tramadol Phase 3 safety study, with no assurance of availability on acceptable terms.
• Termination of the AJ201 license agreement indicates a failure in that product candidate's development under Avenue.
• Inability to utilize the At-the-Market (ATM) facility for capital raises due to Nasdaq delisting.
• Accumulated deficit increased to $104.780 million as of September 30, 2025, from $102.580 million at December 31, 2024.

Risks

• Currently has no drug products for sale and success is dependent on product candidates receiving regulatory approval and successful commercialization.
• Possibility that serious adverse or unacceptable side effects are identified during the development of current or future product candidates.
• Substantial doubt about the ability to continue as a going concern, which may hinder the ability to obtain future financing.
• Significant losses incurred since inception and expectation of continued losses for the foreseeable future.
• Uncertainty related to the timing and amounts expected to be realized from future milestone, royalty, or similar revenue streams, if any.
• Need for substantial additional funding, which may not be available on acceptable terms or at all, potentially forcing delays, reduction, or elimination of product development programs or commercialization efforts.
• Reliance on third parties for several aspects of operations, including clinical data and manufacturing.
• Possibility of not receiving regulatory approval for any or all product candidates, or that such approval may be significantly delayed.
• Even if one or more product candidates receives regulatory approval, they will remain subject to substantial regulatory scrutiny.
• Effects of current and future laws and regulations relating to fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations.
• Effects of competition for product candidates and the potential for new products to emerge that provide different or better therapeutic alternatives.
• Possibility that government or third-party payors fail to provide adequate coverage and payment rates for product candidates or any future products.
• Ability to establish sales and marketing capabilities or to enter into agreements with third parties to market and sell product candidates.
• Exposure to potential product liability claims.
• Related to the protection of intellectual property and potential inability to maintain sufficient patent protection for technology and products.
• Ability to maintain compliance with obligations under intellectual property licenses and funding arrangements with third parties.
• Fortress Biotech, Inc. controls a majority of the voting power of outstanding capital stock and has rights to receive significant share grants annually.
• The OTCID Market is a thinly traded market lacking in liquidity and subject to volatility.
• Common stock may be considered a penny stock and, therefore, may be subject to certain rules that make it difficult for brokers, dealers, or investors to sell the shares.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it develops its product candidates. Additional funding through equity or debt offerings will be required for the potential Phase 3 safety study for IV tramadol, with no assurance of availability on acceptable terms. Research and development activities are expected to decrease due to the termination of the AJ201 program and the sale of BAER-101, but general and administrative costs will continue as the company seeks regulatory approval and commercialization for its remaining product candidate.

Management Comments

• We expect to continue to incur research and development costs and general and administrative costs and incur operating losses for at least the next several years as we continue the development of our product candidates.
• We intend to obtain additional capital through the sale of debt or equity securities or other arrangements to fund our operations, research and development activity or regulatory approval activity; however, there can be no assurance that we will be able to raise the necessary capital under acceptable terms, if at all.
• If we are unable to obtain such additional financing, future operations would need to be scaled back or discontinued.
• We plan to continue to file our required periodic reports and other filings with the SEC.
• We can provide no assurance that our common stock will continue to trade on this market, whether broker-dealers will continue to provide public quotes of our common stock on this market, or whether the trading volume of our common stock will be sufficient to provide for an efficient trading market for existing and potential holders of our common stock.
• We are currently evaluating the feasibility of the safety study [for IV tramadol]. The initiation of the study is subject to the Company obtaining the necessary financing or partnership.

Industry Context

Avenue Therapeutics operates in the highly capital-intensive and risky specialty pharmaceutical sector, focusing on neurologic diseases. The termination of the AJ201 license and the sale of BAER-101 reflect the inherent challenges in drug development, where pipeline rationalization and strategic divestitures are common for smaller biotechs facing funding constraints. The delisting from Nasdaq further isolates the company from mainstream capital markets, a trend seen with smaller, unprofitable biotechs struggling to meet listing requirements. The continued pursuit of IV tramadol, despite past regulatory hurdles and current funding needs, highlights the long development cycles and high costs typical of the industry.

Comparison to Industry Standards

• The company's accumulated deficit of $104.8 million and ongoing operating losses are common for clinical-stage biopharmaceutical companies that have not yet brought a product to market.
• The delisting from Nasdaq due to failing to meet minimum stockholders' equity ($2.5 million) is a significant governance and financial setback, placing the company in a less liquid and less transparent trading environment (OTCID) compared to peers on major exchanges.
• The strategic divestiture of BAER-101 to Axsome Therapeutics, a larger player in the CNS space, is a common strategy for smaller biotechs to monetize assets and reduce R&D burn, similar to how many early-stage companies license out or sell programs to larger pharmaceutical companies.
• The challenges with IV tramadol, including the need for a Phase 3 safety study and securing financing, are typical of the rigorous and costly regulatory pathway for new drug approvals, especially for controlled substances like opioids.

Corporate Governance

Legal Proceedings

• No material legal proceedings pending against the company, other than routine actions and administrative proceedings not expected to have a material adverse effect on business, financial condition, results of operations, or cash flows.

Related Party Transactions

• Fortress Biotech, Inc. (Fortress) is the parent company and controls a majority of voting power.
• Management Services Agreement (MSA) with Fortress resulted in an expense of $0.1 million for the three months ended September 30, 2025, and $0.4 million for the nine months ended September 30, 2025.
• Annual Equity Fee: 22,476 shares of common stock were issued to Fortress on January 2, 2025, representing 2.5% of fully-diluted outstanding equity.
• Financing Equity Fee: $0.1 million was recorded for the nine months ended September 30, 2025, resulting in 23,474 shares of common stock issued to Fortress.
• The Avenue-Baergic Founders Agreement and Avenue-Baergic Management Services Agreement were terminated on November 5, 2025, due to the sale of Baergic.
• Restricted stock in Baergic was granted to Avenue's CEO, Interim CFO/COO, and a Fortress employee, fully vested upon the sale of Baergic to Axsome, entitling them to a portion of future payments and royalties from the Baergic Agreement.

Stakeholder Impact

• Shareholders: Negative impact on liquidity and market price due to Nasdaq delisting; potential dilution from future equity offerings; uncertainty regarding the company's going concern status.
• Employees: Potential impact on job security due to ongoing losses and need for funding, though specific details are not provided.
• Suppliers/Creditors: Increased risk due to going concern doubts and reliance on future financing.

Next Steps

• Secure additional funds through equity or debt offerings for the IV tramadol Phase 3 safety study.
• Initiate the IV tramadol Phase 3 safety study once financing or partnership is secured.
• Continue to develop and attempt to gain regulatory approval for IV tramadol.
• Evaluate market conditions, liquidity profile, and financing alternatives to enhance capital structure.
• File required periodic reports and other filings with the SEC.
• AnnJi to make potential future milestone and royalty payments for AJ201.
• Axsome to make potential future milestone and royalty payments for AXS-17 (formerly BAER-101).

Key Dates

Recommendation

Avenue Therapeutics faces severe challenges, including delisting from Nasdaq, an explicit 'going concern' warning, and a significant reduction in its product pipeline through the termination of the AJ201 license and the sale of BAER-101. While net losses have decreased, this is largely due to reduced R&D spending from divested assets rather than improved core operations. The company has no commercial products, requires substantial additional funding for its sole remaining clinical asset (IV tramadol), and has lost access to its ATM facility. The move to the illiquid OTCID market further exacerbates investment risk. Given the fundamental financial instability, lack of clear path to profitability, and significant operational risks, a strong sell recommendation is warranted.

Keywords

Avenue Therapeutics, ATXI, 10-Q, Quarterly Report, SEC Filing, Biotechnology, Pharmaceuticals, Neurologic Diseases, IV Tramadol, BAER-101, AXS-17, Nasdaq Delisting, Going Concern, Clinical Trials, FDA Approval, Drug Development, Financial Results, Net Loss, Research and Development, Capital Raise, Asset Sale, AnnJi License, Axsome Therapeutics, OTC Markets